Skip to main content

Table 3 Association between hormone replace therapy and intracranial meningioma in post-menopausal women

From: Hormonal exposures and the risk of intracranial meningioma in women: a population-based case-control study

Exposure* Cases n Controls n OR (95% CI)†
Hormone replacement therapy (HRT)
Never 38 58 Referent
Past 40 73 0.7 (0.4 – 1.3)
Current use on reference date 23 41 1.0 (0.4 – 2.2)
Years of HRT use
Never 38 58 Referent
Up to 5 years 28 43 0.9 (0.4 – 1.7)
More than 5 years 32 65 0.9 (0.5 – 1.7)
First HRT exposure relative to reference date
Never 38 58 Referent
1–9 years before 30 44 0.9 (0.4 – 1.9)
10 or more years before 31 62 0.9 (0.5 – 1.6)
Type of HRT preparation
None 38 58 Referent
Estrogen 33 66 0.9 (0.5 – 1.6)
Estrogen and Progestin 24 33 1.3 (0.6 – 2.8)
  1. * Reported exposure before reference date, which for a case and her two matched controls was the date the case had surgery for her meningioma.
  2. † Odds ratio (OR) and 95% confidence intervals (CI) estimated from multivariable conditional logistic regression including continuous age and three categories of education (high school or less, some college or trade school, and college graduate or graduate school) as confounding variables. None of the tests for linear trend was significant.